BridgeBio Pharma (BBIO) director exercises options and sells 10,000 shares
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BridgeBio Pharma director Scott Randal W. exercised stock options for 10,000 shares of common stock at $16.75 per share and sold 10,000 shares in open-market transactions on May 15, 2026. The sales occurred in multiple trades at weighted average prices around the high‑$60 range under a pre-arranged Rule 10b5-1 sales plan. Following these transactions, he holds 11,589 shares directly and 4,000 shares indirectly through Thinking Bench Capital LLC.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Net Seller: 10,000 shares ($671,456)
Net Sell
7 txns
Insider
Scott Randal W.
Role
null
Sold
10,000 shs ($671K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (Right to Buy) | 10,000 | $0.00 | -- |
| Exercise | Common Stock | 10,000 | $16.75 | $168K |
| Sale | Common Stock | 6,200 | $66.6878 | $413K |
| Sale | Common Stock | 2,088 | $67.5302 | $141K |
| Sale | Common Stock | 1,512 | $68.2303 | $103K |
| Sale | Common Stock | 200 | $69.12 | $14K |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 21,501 shares (Direct, null);
Common Stock — 21,589 shares (Direct, null);
Common Stock — 4,000 shares (Indirect, By Thinking Bench Capital LLC)
Footnotes (1)
- This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on June 27, 2025. Represents the weighted average sale price of the shares sold from $66.08 to $67.07 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $67.10 to $68.09 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. Represents the weighted average sale price of the shares sold from $68.10 to $68.40 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote. One-third of the shares underlying the option will vest on June 21, 2024; thereafter, one-third of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.
Key Figures
Shares sold: 10,000 shares
Sale prices: $66.69–$69.12 per share
Options exercised: 10,000 shares
+4 more
7 metrics
Shares sold
10,000 shares
Open-market sales of common stock on May 15, 2026
Sale prices
$66.69–$69.12 per share
Weighted average prices across four sale blocks
Options exercised
10,000 shares
Stock option exercise (Code M) on May 15, 2026
Exercise price
$16.75 per share
Stock Option (Right to Buy) conversion price
Direct holdings after
11,589 shares
Common stock directly owned after transactions
Indirect holdings after
4,000 shares
Common stock held via Thinking Bench Capital LLC
Net share change
10,000 shares
ExerciseShares 10,000 vs. SellShares 10,000 (net-sell direction)
Key Terms
Rule 10b5-1 sales plan, weighted average sale price, Stock Option (Right to Buy), Board of Directors, +1 more
5 terms
Rule 10b5-1 sales plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person"
weighted average sale price financial
"Represents the weighted average sale price of the shares sold from $66.08 to $67.07 per share"
Stock Option (Right to Buy) financial
"Stock Option (Right to Buy) with an exercise or conversion price of 16.7500"
Board of Directors financial
"subject to the optionee's continued service on the Board of Directors of the Company"
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
derivative exercise/conversion financial
"transaction_action: derivative exercise/conversion with transaction code M"
FAQ
What insider activity did BridgeBio Pharma (BBIO) report for Scott Randal W.?
BridgeBio Pharma reported that director Scott Randal W. exercised stock options for 10,000 shares and sold 10,000 common shares in open-market transactions. These trades occurred on May 15, 2026, and were executed under a pre-arranged Rule 10b5-1 sales plan.
What stock options did the BridgeBio Pharma (BBIO) director exercise?
The director exercised stock options covering 10,000 BridgeBio Pharma common shares at an exercise price of $16.75 per share. These options were part of a grant that vests in three annual installments, fully vesting by June 21, 2026, contingent on continued board service.
Were the BridgeBio Pharma (BBIO) insider sales made under a trading plan?
Yes. The filing states the sales were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Such plans pre-schedule trades, meaning the timing of these sales was determined in advance rather than being a discretionary, real-time market decision.
What is the nature of the indirect BridgeBio Pharma (BBIO) holdings in this Form 4?
The Form 4 shows 4,000 BridgeBio Pharma common shares held indirectly through Thinking Bench Capital LLC. This indicates the reporting person’s economic interest is partly held via that entity, rather than solely in his own name as directly owned stock.